2023-07-04 22:04:13
pharmaceutical organization Signed a memorandum of understanding with SK bioscience Co., Ltd., Republic of Korea, to produce influenza vaccine from cell cultures in Thailand. It is expected that next year the vaccine will be ready to be packaged. Phase 2 will receive technology transfer from upstream to downstream. Ready to expand the production of other vaccines such as shingles prevention
Dr. Opas Karnkawinpong The Permanent Secretary of the Ministry of Public Health (Public Health) presided over the signing of a memorandum of understanding between Dr. Mingkwan Suphanpong, Director of the Government Pharmaceutical Organization (GPO) and Mr. An Jae Yong, CEO of SK Bioscience Company Limited, Republic of Korea. with Mr. Jon Jo Young, Chargé d’affaires, Royal Thai Embassy Republic of Korea in Thailand witness
Dr. Opas said that Thailand attended a ratification ceremony with the International Vaccine Institute (IVI) in Seoul, Republic of Korea on October 25, 2022 to mobilize international cooperation in building the future of vaccines for national public health security. which the development of vaccine technology resulting in more effective treatment of the disease Vaccine personnel must constantly adapt and learn technology. to deal with changes immediately This MOU paves the way for the sharing of knowledge and expertise of the two countries. with the same goal, which is to strengthen the health systems of both countries to be stable Including improving the quality of life of the people to have better access to vaccines that are important to health Dr. Mingkwan said that the vaccine factory of the Ministry of Public Health has researched and developed the production of influenza vaccines in case of outbreaks and seasons. until success and from the COVID-19 crisis The FDA receives government funding to build capacity and prepare for new and re-emerging diseases. by starting research and development of a COVID-19 vaccine from upstream to downstream using egg production technology and has also begun to develop vaccines made from cell cultures
The signing of the agreement establishes a partnership with SK Bioscience, a manufacturer of inactivated, tri- and quadrivalent cell culture seasonal influenza vaccines, in the form of Ready to Fill Bulk vaccines, and Technology transfer of packaging process for the production of finished vaccines (Drug Product) by the FDA in order to use the facility and support system. resources the most worthwhile As well as creating knowledge and expertise for personnel as well, SK Science will be a consultant and transfer technology in production processes and various knowledge bodies to the FDA to create international standards. Study the opportunity to establish a major pharmaceutical manufacturing plant in Thailand.
Mr. An Jae Yong said that the reason for choosing The GPO joins hands because Thailand and the GPO are ready. supported by the government believe in cooperation In the past, we had a good relationship with the Thai government through many channels. And vaccines are among the long list of previous collaborations. This collaboration will be successful in technology transfer. and place of production The PPP is regarded as the center of the region.
As for how long the technology transfer period will take and when will it start to be used? with a preliminary agreement already Next year should be the vaccine in the form of a ready-to-pack or packaged vaccine. which is the nature of the middle water Then it will enter Phase 2, which will transfer technology from upstream to downstream. It is expected to be no more than 2 years. The vaccines in the GPO pipeline include both the influenza vaccine and the GPO Vac COVID vaccine. This signing is considered a big step. Because South Korea has many other vaccine production issues that are expected to transfer technology, such as the shingles vaccine.
On the side of Dr. Nakorn Premsri, director of the National Vaccine Institute, said that the vaccines that Thailand currently produces are:
1. BCG vaccine or tuberculosis vaccine Produced by Queen Saovabha Memorial Institute
2. Acellular pertussis vaccine from Bionet Asia Co., Ltd.
3. JD vaccine against encephalitis It is a technology transfer and packaging by Global Biotech Products Co., Ltd., a joint venture of the Government Agency.
In addition, there is an influenza vaccine from the Ministry of Public Health. It is expected to be registered in 2023 and is about to cooperate with the company. SK as well in the shingles vaccine section
Vaccines made from cell cultures are a new technology. It is hoped that from the beginning of the cooperation, it will be further developed for research and production of own vaccines from other cells. which is very important for dealing with a pandemic Because it makes it faster to produce. In the past, the Vaccine Institute has done a lot to build Thailand’s vaccine security, for example, to build the potential of research and development of vaccine production in important platforms. by mRNA vaccine Support for funding teams of the Faculty of Medicine Chulalongkorn University Associated with Bionet Asia, Viral Vaccine supports NSTDA. Biotech, KMUTT, Siam Bioscience, killed vaccines, support the FDA and subunit protein vaccines Support Biya company. In addition, there is a team of standardized laboratory animals. There is a human research team. All are national teams that can work from now on forward. In maintaining and enhancing the potential as well as trying to find cooperation from foreign countries to jointly develop make Thailand act faster
Multiplatform support for vaccine production This gives the opportunity to produce vaccines by ourselves to cope with various diseases. because they do not know what the new disease outbreak is and do not know which platform will work well which COVID-19 may tell us one way But if encountering a new disease, it could be another form. like when there was no covid-19 People still don’t know about mRNA vaccines, viral vector vaccines. therefore preparing for the future And it’s a matter of investment. Hopefully the government will support it as it is a matter of continued investment.
#Influenza vaccine production
# cell culture
CR: Thank you for the information-image Hfocus.
1688580080
#Expect #years #ThaiKorea #produces #influenza #vaccine #cell #cultures